RSS

respiratory syncytial virus (RSV)

Biotechnology company, VirionHealth, has raised series A funding of up to £13 million from an international investment group dedicated to the life sciences, Abingworth. more

News

Regeneron Pharmaceuticals has announced plans to discontinue further clinical development of its antibody, suptavumab, for respiratory syncytial virus, as it has not met the primary endpoint of preventing infections in infants in the Phase III study more

News